Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer

NCT00126503 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00126503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2005
Completion date
February 29, 2012
Enrollment
73 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chromophobe renal cell carcinoma, clear cell renal cell carcinoma, papillary renal cell carcinoma, recurrent renal cell carcinoma, sarcomatoid renal cell carcinoma, stage iv renal cell cancer